Cystic Fibrosis Foundation - Click here for homepage
Stay Informed  |  Volunteer  |  Clinical Trials

In This Section

Quick Links

Find a Chapter

Get Assistance

Get Assistance - Cox Boys
We are here to help people with CF get the insurance coverage they need. Hear how the Foundation helped the Cox family.

Join us on Facebook!  Facebook 
Follow us on Twitter!   Twitter
Follow us on Instagram!  Instagram 
Add us to your circle in Google+!


Subscribe to our channel on YouTube!  YouTube  



Bookmark and Share   Print  

Vertex Presents New Data from Late-Stage Studies of CF Drug Ivacaftor

June 12, 2014

Vertex Pharmaceuticals Inc. announced it is presenting new ivacaftor (Kalydeco™) data at the European Cystic Fibrosis Society Conference in Gothenburg, Sweden, June 11 - 14. The presentations include:

  • Data from a Phase 3 trial and long-term extension studies, which showed that ivacaftor reduced the loss of lung function by half over a period of three years in people with the G551D mutation of CF, compared to a group of untreated patients.

  • Data from a rollover study of ivacaftor in people with the R117H mutation, which support earlier results from a Phase 3 study that demonstrated lung function improvements in people with CF ages 18 and older.

  • Data from a Phase 3 trial of ivacaftor in people with certain CF mutations closely related to the G551D mutation, which showed that previously reported lung function improvements were maintained through 24 weeks.

Read the Vertex press release.

The Cystic Fibrosis Foundation is an accredited charity of the Better Business Bureau.